Suppr超能文献

在进行联合介入操作前是否应停止新型口服抗凝剂?前瞻性研究的证据表明可继续治疗。

To stop or not to stop novel oral anticoagulants prior to performing joint interventional maneuvers? Evidence from a prospective study that the therapy can be maintained.

机构信息

"Iuliu Hațieganu" University of Medicine and Pharmacy Cluj-Napoca, Cluj-Napoca, Romania.

Rheumatology Division, Rehabilitation Clinical Hospital Cluj-Napoca, Viilor str. No 46-50, 400347, Cluj-Napoca, Romania.

出版信息

Clin Rheumatol. 2024 Sep;43(9):2983-2992. doi: 10.1007/s10067-024-07048-6. Epub 2024 Jul 15.

Abstract

Anticoagulation is common in patients undergoing routine musculoskeletal interventional maneuvers. Previous retrospective studies have established the safety of continuing anticoagulation with novel oral anticoagulants (NOACs) when performing this kind of interventions. Indeed, ultrasound (US)-guided interventional maneuvers have shown a superior safety profile compared to blind anatomical maneuvers. To evaluate prospectively the periprocedural bleeding events in NOAC-anticoagulated patients undergoing interventional articular or periarticular procedures. Consecutive patients diagnosed with inflammatory or degenerative rheumatologic pathology requiring interventional maneuvers were prospectively recruited. Group 1 was treated with NOACs, group 2 was treated with vitamin K antagonists, and group 3 was not anticoagulated. Prior to the international maneuver, NOAC therapy was continuously administered, in regimens dictated by the underlying anticoagulation indication. Demographics, comorbidities, laboratory parameters, locally administered medication (corticosteroids or viscosupplementation), interventional maneuver location, needle size, and local bleeding events were recorded. Post-procedural control was performed at 30 min, 48 h, and 7 days. No articular/periarticular bleeding event occurred in patients treated with NOACs, regardless of their type and dosage, locally administered medication, needle size, location, and number of interventions per individual. Several patients in all groups developed small superficial ecchymoses at the injection site. Our results suggest that NOACs are safe to be used in a continuous regimen prior to US-guided injections, even as dual antithrombotic therapy (in combination with aspirin). The use of lower gauge needles, chosen for viscosupplementation therapy, was not burdened with adverse effects on the procedural outcome. Key Points • Currently, no prospective studies have been performed to establish the safety of continuous NOAC anticoagulation when performing routine intra- or periarticular interventional maneuvers. • The study offers an extensive view on a wide spectrum of intra- and periarticular interventional maneuvers including anatomic targets and needle sizes that were not previously assessed. • The study offers a perspective into performing repetitive maneuvers in the same patient, both over a short time and at longer intervals. • The zero periprocedural bleeding risk observed in our study may reassure practitioners and suggest that US-guided interventional therapeutic interventions are safe in patients treated with a continuous regimen of different NOACs.

摘要

抗凝治疗在接受常规肌肉骨骼介入操作的患者中很常见。先前的回顾性研究已经证实,在进行此类介入操作时,继续使用新型口服抗凝剂(NOAC)进行抗凝治疗是安全的。事实上,超声(US)引导的介入操作与盲目解剖操作相比,具有更高的安全性。前瞻性评估接受关节内或关节周围介入操作的 NOAC 抗凝患者的围手术期出血事件。连续招募诊断为需要介入操作的炎症性或退行性风湿性病理的患者。第 1 组接受 NOAC 治疗,第 2 组接受维生素 K 拮抗剂治疗,第 3 组未抗凝。在国际操作之前,根据潜在抗凝适应证,连续给予 NOAC 治疗。记录患者的人口统计学、合并症、实验室参数、局部应用药物(皮质类固醇或粘性补充剂)、介入操作部位、针的大小和局部出血事件。术后 30 分钟、48 小时和 7 天进行术后控制。接受 NOAC 治疗的患者无论其类型和剂量、局部应用药物、针的大小、位置和个体的介入次数如何,均未发生关节/关节周围出血事件。所有组的几个患者在注射部位出现小的浅表瘀斑。我们的结果表明,即使在双联抗血栓治疗(与阿司匹林联合使用)中,NOAC 也可以安全地在 US 引导下注射前连续使用。选择用于粘性补充治疗的较小口径针不会对程序结果产生不利影响。关键点 • 目前,尚无前瞻性研究确定在进行常规关节内或关节周围介入操作时,连续使用 NOAC 抗凝治疗的安全性。 • 该研究广泛评估了广泛的关节内和关节周围介入操作,包括以前未评估的解剖靶标和针的大小。 • 该研究提供了在同一患者中短时间和长时间内重复操作的视角。 • 我们研究中观察到的零围手术期出血风险可能使从业者放心,并表明在接受不同 NOAC 连续治疗的患者中,US 引导的介入治疗干预是安全的。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验